Strategic collaboration established with InnoHK C2i
NovoBay and InnoHK C2i signed an MoU to advance research evaluation, evidence generation, rapid molecular testing, genomic surveillance and translational research.
LATEST MEDIA RELEASEStrategic Collaboration
Strategic Collaboration
Advancing Translational Research
InnoHK C2i and NovoBay Biotech Establish Strategic Collaboration on Rapid Molecular Testing, Genomic Surveillance and Translational Research
The collaboration creates a structured framework for evaluating molecular diagnostic and sequencing technologies across oncology, infectious disease surveillance and other public health applications.
Read the full media release →
COMPANY MILESTONEStarting in Hong Kong
Starting in Hong Kong
Building a Collaborative Network
NovoBay incorporated in Hong Kong
NovoBay Biotechnology Company Limited was formally established and began building a collaborative network connecting diagnostics and pharmaceutical companies with clinical, research and commercial partners.
Focus AreasAddressing Critical Commercialization Questions
Addressing Critical Commercialization Questions
Developing Practice-Based Insights
Market Expansion & Access
Consider entry sequence and readiness in relation to product stage, evidence status, target markets and stakeholders.
Research & Clinical Collaboration
Explore how research questions, samples and workflows, collaboration conditions and multi-party responsibilities can form actionable arrangements.
Partner & Channel Development
Share practical considerations in partner identification, partnership-model assessment and engagement with key institutions.
Explore NovoBay's collaboration focus
Contact us to discuss a project, media inquiry or ecosystem collaboration.